PharmaVoice Logo

Healthcare Leaders Hub

AHA26: Boehringer’s survodutide establishes CV safety in SYNCHRONIZE-CVOT

Pharma Tech

AHA26: Boehringer’s survodutide establishes CV safety in SYNCHRONIZE-CVOT

KOLs interviewed by GlobalData were more optimistic about survodutide’s potential in fatty liver disease (MASLD) than weight loss.

Read Full Article
AHA26: Semaglutide’s real-world CV benefits highlight importance of persistence

Pharma Tech

AHA26: Semaglutide’s real-world CV benefits highlight importance of persistence

Real-world semaglutide CV outcomes mirror clinical trials, with greater treatment persistence linked to better outcomes.

Read Full Article
BIO Europe: Financing, AI and geopolitics shape biotech discourse 

Pharma Tech

BIO Europe: Financing, AI and geopolitics shape biotech discourse 

Speakers at BIO-Europe 2026 noted that European biotechs must be agile and adaptable in times of geopolitical and financial upheaval.

Read Full Article
Top 20 Cardiometabolic Prescription Drugs of 2026

PharmaShots

Top 20 Cardiometabolic Prescription Drugs of 2026

Shots:  20. Xultophy  Non-Proprietary Name: Insulin degludec/liraglutide Company: Novo Nordisk First Approved: EU (2014), US (2016) FY2025 Revenue: $0.72B FY2024 Revenue: $0.62B YoY Growth: +15.7%  19. Kerendia  Non-Proprietary Name: Finerenone Company: Bayer First Approved: US (2021), EU (2022) FY2025 Revenue: $0.97B FY2024 Revenue: $0.48B YoY Growth: +102%  18. Leqvio  Non-Proprietary Name: Inclisiran Company: Novartis First Approved: US (2021), EU (2020) FY2025 Revenue: $1.19B FY2024 Revenue: $0.75B YoY Growth: +58.9%  17.… The post Top 20 Cardiometabolic Prescription Drugs of 2026 appeared first on PharmaShots.

Read Full Article
FDA puts commissioner’s priority voucher framework on ice  

Pharma Tech

FDA puts commissioner’s priority voucher framework on ice  

Experts consistently questioned how vouchers were awarded, along with critiquing its wider industry benefits.

Read Full Article

Sponsored content

Featured promotional

Jeplus.in
Sponsored

Jeplus.in

Purchase All Medicines.Get 10% Offer

News

Latest stories

ET Pharma

Nov 15, 2026, 11:49 AM

Alembic Pharma receives USFDA approval for lung cancer drug

Alembic Pharmaceuticals has received final approval from the US FDA for its Binimetinib tablets, intended for lung cancer treatment. These tablets are therapeutically equivalent to Array BioPharma Inc.'s Mektovi. As a first ANDA applicant, Alembic will benefit from 180 days of exclusivity for both the 15 mg and 45 mg dosages.

ET Pharma

Nov 15, 2026, 11:44 AM

Maharashtra FDA seizes Rs 1.39 crore nutraceuticals containing rejected ingredients

The Maharashtra Food and Drug Administration seized health supplements valued at Rs 1.39 crore from various establishments statewide. A significant amount of the seized stock was found at Kanchan Pharma Pvt Ltd's warehouse in Bhiwandi. The action targeted products containing ingredients whose approvals had been denied by the Food Safety and Standards Authority of India. The crackdown is part of a broader initiative called 'Safe Food, Safe Maharashtra'.

ET Pharma

Nov 14, 2026, 2:27 AM

Bristol Myers to merge scientific, clinical teams under new R&D structure

Current Chief Research Officer Robert Plenge will leave in March 2027 after the transition.

ET Pharma

Nov 14, 2026, 2:25 AM

Breakthrough HIV drug sees 18 patent filings, may delay affordable generics

In a letter to the department for promotion of industry and internal trade, patient groups demanded that the patent office must rigorously examine and reject the company's secondary patent applications.

ET Pharma

Nov 14, 2026, 2:22 AM

Compulsory Licensing of Drugs Only After Exhausting All Other Measures: Pharma secy

The government plans to address the high costs of innovative medicines by first negotiating prices. Compulsory licensing will be considered only after other alternatives are exhausted. Trade margins on high-cost drugs are being examined to enhance affordability. Discussions are ongoing with pharmaceutical companies to improve access and affordability of patented drugs. The government is also working on initiatives to support the local pharmaceutical manufacturing sector.

Pharma Tech

Nov 13, 2026, 7:53 PM

AHA26: Boehringer’s survodutide establishes CV safety in SYNCHRONIZE-CVOT

KOLs interviewed by GlobalData were more optimistic about survodutide’s potential in fatty liver disease (MASLD) than weight loss.

News

Latest industry coverage

Google News

Nov 15, 2026, 11:36 PM

Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026... - Quantisnow

Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026...  Quantisnow

Google News

Nov 15, 2026, 11:30 PM

Ascentage Pharma Announces Inclusion of Lisaftoclax in - GlobeNewswire

Ascentage Pharma Announces Inclusion of Lisaftoclax in  GlobeNewswire

Google News

Nov 15, 2026, 11:19 PM

Rohto Pharmaceutical Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models - Simply Wall St

Rohto Pharmaceutical Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models  Simply Wall St

Google News

Nov 15, 2026, 10:10 PM

Namwon to leverage national medical grad school for health tourism and biotech - Chosunbiz

Namwon to leverage national medical grad school for health tourism and biotech  Chosunbiz

Google News

Nov 15, 2026, 9:12 PM

Asia's Premier News Agency - India News, Business & Political, National & International, Bollywood, Sports - ANI News

Asia's Premier News Agency - India News, Business & Political, National & International, Bollywood, Sports  ANI News

Google News

Nov 15, 2026, 9:06 PM

Fatty Hepatitis Market Draws Big Pharma, K-Bio - 조선일보

Fatty Hepatitis Market Draws Big Pharma, K-Bio  조선일보

Google News

Nov 15, 2026, 7:34 PM

FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug - Investor's Business Daily

FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug  Investor's Business Daily

Google News

Nov 15, 2026, 7:17 PM

What Lotus Pharmaceutical Doubters Saw Before A 51% Fall - Simply Wall St

What Lotus Pharmaceutical Doubters Saw Before A 51% Fall  Simply Wall St

Google News

Nov 15, 2026, 6:46 PM

Ethyl Methyl Cellulose (EMC) Market To 2035: Construction and Pharma Demand Fuel Expansion - News and Statistics - IndexBox

Ethyl Methyl Cellulose (EMC) Market To 2035: Construction and Pharma Demand Fuel Expansion - News and Statistics  IndexBox

Sponsored placement

Featured promotions

Jeplus.in
Sponsored

Jeplus.in

Purchase All Medicines.Get 10% Offer